Jad Chahoud Shared Article on Cemiplimab Reducing Recurrence in High-Risk cSCC
Jad Chahoud, Genitourinary Medical Oncologist at Moffitt Cancer Center, shared a post on X about a paper by Danny Rischin et al. published in NEJM:
“Phase 3 C-POST trial: Adjuvant cemiplimab slashed recurrence risk in high-risk cutaneous SCC (HR 0.32).
24-mo DFS: 87% vs 64% with placebo.”
Title: Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
Authors: Danny Rischin, Sandro Porceddu, Fiona Day, Daniel P. Brungs, Hayden Christie, James E. Jackson, Brian N. Stein, Yungpo Bernard Su, Rahul Ladwa, Gerard Adams, Samantha E. Bowyer, Zulfiquer Otty, Naoya Yamazaki, Paolo Bossi, Amarnath Challapalli, Axel Hauschild, Annette M. Lim, Vishal A. Patel, Joanna L. Walker, Maite De Liz Vassen Schurmann, Paola Queirolo, Javier Cañueto, Flavio Augusto Ferreira da Silva, Alexander Stratigos, Alexander Guminski, Charles Lin, Fernanda Damian, Lukas Flatz, Anne E. Taylor, David R. Carr, Samuel Harris, Dmitry Kirtbaya, Gaëlle Quereux, Piotr Rutkowski, Nicole Basset-Seguin, Nikhil I. Khushalani, Caroline Robert, Haisong Ju, Camryn Joseph, Shikha Bansal, Chieh-I Chen, Frank Seebach, Suk-Young Yoo, Israel Lowy, Priscila Goncalves, Matthew G. Fury
You can read the Full Article on NEJM.
More posts featuring Jad Chahoud.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023